Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $112.27 USD
Change Today -0.58 / -0.51%
Volume 11.3M
As of 8:10 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

gilead sciences inc (GILD) Snapshot

Open
$113.15
Previous Close
$112.85
Day High
$113.37
Day Low
$111.85
52 Week High
10/31/14 - $116.83
52 Week Low
06/9/14 - $78.50
Market Cap
165.0B
Average Volume 10 Days
11.4M
EPS TTM
$8.83
Shares Outstanding
1.5B
EX-Date
06/12/15
P/E TM
12.7x
Dividend
$1.72
Dividend Yield
--
Current Stock Chart for GILEAD SCIENCES INC (GILD)

gilead sciences inc (GILD) Details

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical nee in North America, South America, Europe, and the Asia-Pacific. The company’s products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with Bristol-Myers Squibb Company', Janssen R&D Ireland, and Japan Tobacco Inc. to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.

7,000 Employees
Last Reported Date: 02/25/15
Founded in 1987

gilead sciences inc (GILD) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.6M
President and Chief Operating Officer
Total Annual Compensation: $1.0M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $797.6K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $920.6K
Executive Vice President of Corporate & Medic...
Total Annual Compensation: $814.3K
Compensation as of Fiscal Year 2014.

gilead sciences inc (GILD) Key Developments

Gilead Sciences Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 02:20 PM

Gilead Sciences Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 02:20 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Paul Rutherford Carter, Executive Vice President of Commercial Operations.

Gilead Sciences Inc. - Shareholder/Analyst Call

Annual Stockholders Meeting

Mylan N.V Announces Distribution Agreement to Unveils Gilead Sciences (Euro)(Tm) Sovaldi Tablets in India

Mylan N.V. announced the availability of Sovaldi (sofosbuvir 400mg tablets) in India for the treatment of chronic hepatitis C infection. Under an exclusive distribution agreement, Mylan Pharmaceuticals Private Limited's sales force has launched Gilead Sciences' Sovaldi (sofosbuvir 400mg tablets) in India. Sovaldi is indicated for the treatment of chronic hepatitis C infection, a blood-borne infectious disease, as a component of a combination antiviral treatment regimen. It is estimated that approximately 12 million people are chronically infected with hepatitis C in India. A licensing and technology transfer agreement reportedly grants Mylan the non-exclusive rights to manufacture and distribute generic sofosbuvir and generic ledipasvir/sofosbuvir and, upon US FDA approval, the investigational NS5A inhibitor GS-5816 and single tablet regimen of sofosbuvir/GS-5816 in 91 developing countries.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GILD:US $112.27 USD -0.58

GILD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $66.59 USD -0.88
Amgen Inc $156.26 USD -1.09
GlaxoSmithKline PLC 1,454 GBp -6.50
Merck & Co Inc $60.89 USD +1.19
Sanofi €89.15 EUR -3.12
View Industry Companies
 

Industry Analysis

GILD

Industry Average

Valuation GILD Industry Range
Price/Earnings 12.9x
Price/Sales 6.1x
Price/Book 9.7x
Price/Cash Flow 11.7x
TEV/Sales 5.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GILEAD SCIENCES INC, please visit www.gilead.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.